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Abstract
Of 109 clinical Escherichia coli isolates from two major tertiary
hospitals in Lagos (University Teaching Hospital and the National
Orthopaedic Hospital Igbobi), 14 (12.8%) extended-spectrum
beta-lactamse (ESBL) producers were characterized using PCR
and sequencing, ERIC-PCR and multilocus sequence typing. All
ESBL-producing isolates encoded only the CTX-M-15 gene.
Clonal group ST131 (35.7%) was the predominant ST, followed
by ST617 (28.6%). Isolated cases of other sequence types were
also observed. Plasmid-mediated quinolone resistance genes qnrA,
qnrB1 and aac-(6¢)-lb-cr were detected among these ESBL isolates
of different clonal groups. This is the ﬁrst description of the clo-
nality of CTX-M-15-producing E. coli from Nigeria. The presence
of diverse clonal lineages shows the continuing potential for
genetic diversiﬁcation and emergence of new epidemic strains.
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The horizon of antimicrobial resistance in Escherichia coli has
broadened with the emergence of broad-spectrum resistance
to large families of antimicrobial agents including b-lactams.
The CTX-M family of extended-spectrum b-lactamase (ESBL)
has emerged as the most prevalent ESBL type with CTX-M-
producing E. coli strains regarded as major global pathogens
showing multiple-antibiotic-resistance phenotype. This has
made E. coli infections increasingly difﬁcult to treat [1–5].
More worrisome is the pandemic emergence amongst the
ESBL-producing E. coli of the clone sequence type 131
(ST131), reportedly occurring in many countries. In Nigeria,
ESBL types reported include blaSHV, blaTEM, blaVEB, blaOXA and
blaCMY [6,7], while ESBL CTX-M-15 has been reported only
in E. coli and Klebsiella spp. [8,9]. However, there is a paucity
of data from Nigeria with regards to the genetic lineages of
ESBL-producing E. coli implicated in infection. This study
therefore, investigated within a period of 8 months, the
major clonal complex circulating among ESBL-producing
strains of clinical E. coli obtained from tertiary hospitals in
Lagos using the MLST scheme developed by M. Achtman and
others [10], and determined the association between genetic
clones, ESBL production and ﬂuoroquinolone resistance.
A total of 109 E. coli isolates were received from the
microbiology laboratories of two tertiary hospitals in Lagos
(Lagos University Teaching Hospital (LUTH), n = 79;
National Orthopaedic Hospital Igbobi (NOHI), n = 30)
between June 2008 and January 2009. Only one strain per
patient was included in this study.
Antimicrobial susceptibility testing of the isolates was per-
formed with the VITEK 2 AST-GN13 card. E. coli ATCC
25922 and E. coli ATCC 35218 were used as control strains.
Furthermore, the minimal inhibitory concentrations (MICs) of
ceftazidime, cefotaxime, ciproﬂoxacin and imipenem were
conﬁrmed using the Etest strips according to the manufac-
turer’s instructions and the CLSI standard for the clinical
breakpoints (CLSI 2009). The ESBL Etest strips with ceftazi-
dime ± clavulanate (TZ/TZL) and cefotaxime ± clavulanate
(CT/CTL) (AB Biodisk, bioMe´rieux SA, Marcy l’Etoile, France)
and the double disk synergy tests (DDSTs) were used to con-
ﬁrm the presence of ESBL production following the CLSI
guidelines [11]. Of these 109 isolates, 14 (12.8%) were ESBL
producers and were resistant to ceftazidime and cefotaxime
with MIC of >16 lg/mL. This resistance to the expanded
cephalosporins coexisted with resistance to ciproﬂoxacin
(MIC ‡ 32 lg/mL) in these ESBL isolates. However, they
were all sensitive to the carbapenems.
PCR ampliﬁcation of various resistance genes was per-
formed as previously described, using published primers for
b-lactamase genes blaTEM, blaCTX-M, blaCMY, blaSHV [12] and
plasmid encoded quinolone resistance genes qnrA/B/S,
aac-(6¢)-1b-cr and qepA [13]. The CTX-M ESBL gene was
detected in the identiﬁed ESBL-positive isolates in association
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with plasmid-mediated quinolone resistance (PMQR) genes
(qnrA1 and qnrB1) in four of these isolates. All the ESBL iso-
lates but two encoded the ﬂuoroquinolone-modifying acetyl-
transferase gene aac-(6¢)-lb-cr (Table 1). The strains with
positive PCR amplicons were selected for sequencing on the
ABI Prism 3100 genetic analyser (Applied Biosystems, Darm-
stadt, Germany). The nucleotide sequences were compared
with the previously described sequences in the GenBank
database using BLAST (http://blast.ncbi.nlm.nih.gov/) and all
the CTX-M-producing isolates were found to harbour the
CTX-M-15 ESBL gene. The genetic environment of the
blaCTX-M gene was determined using ISCEp1 primers as
described by Saladin et al. [14].
Genotypic analysis of CTX-M-15-positive isolates was per-
formed using the enterobacterial repetitive intergenic con-
sensus polymerase chain reaction (ERIC-PCR) with ERIC 2
primers [15]. MLST was performed to conﬁrm the presump-
tive clonal group assignments of the CTX-M-15-positive
E. coli isolates. ERIC-PCR showed four of the 14 blaCTX-M-15-
positive isolates forming two pairs of clusters showing identi-
cal patterns, but with difference in their resistance pattern.
All the other ESBL isolates in this study were genetically
unrelated based on their discriminative patterns following
comparison by visual inspection. By MLST, ST131 (35.7%)
was the predominant clonal group established among these
strains and was closely followed by ST Complex (STC) 10
(28.6%). Other sequence types found among these ESBL
strains included ST295, ST501, ST23 and ST448. ST23 and
ST448 were identiﬁed in the Orthopaedic Hospital (NOHI)
while all the other STs were found in LUTH. Of the ﬁve
ST131 isolates, 60% were from urine samples. Three differ-
ent clusters were seen among the six STCs/STs of the E. coli
strains. ST131, ST501 and ST448 appear to be closely
related, ST23 complex ST612 and ST295 were grouped
together, while ST10 complex ST48 and ST617 formed a
third cluster group (Fig. 1). Strains with different proﬁles but
the same sequence type suggest the acquisition of different
antibiotic resistance genes and unique DNA rearrangement
while strains with the same sequence type and identical pat-
tern indicate the possibility of a clonal spread.
This study showed the predominance of the ST131 clone
among the CTX-M-15 ESBL E. coli, of which 60% were uro-
pathogenic with plasmid-mediated resistance to quinolones.
This is in agreement with reports that state that ST131
strains are major extended spectrum cephalosporin-resistant
and ciproﬂoxacin-resistant uropathogenic strains having plas-
mid-mediated quinolone resistance [16–18]. Two recent
studies from Tunisia and South Africa have also shown the
emerging prevalence of CTX-M-producing E. coli of clonal
complex 131 in Africa [1,19].
TABLE 1. Genetic lineage of ESBL-producing Escherichia coli from Nigeria and associated resistance genes
Strain (hospital) and source ESBL and resistance genes Sequence type
4 h (LUTH) urine CTX-M-15, aac-(6¢)-lb-cr, qnrB1 ST131
45 h (LUTH) urine CTX-M-15, aac-(6¢)-lb-cr ST131
75 k (LUTH) semen (2 infertility)
213 b (LUTH) urine CTX-M-15 ST131
73 k (LUTH) wound swab (chronic leg ulcer)
43 h (LUTH) stool CTX-M-15, aac-(6¢)-lb-cr ST10 complex
28 h (NOHI) wound swab CTX-M-15, aac-(6¢)-lb-cr ST23 complex
38 h (LUTH) stool CTX-M-15, aac-(6¢)-lb-cr ST501
5 k (LUTH) urine CTX-M-15, aac-(6¢)-lb-cr, qnrA1 ST617 (ST10 complex)
101 k (LUTH) urine (PID)
103 k (LUTH) blood (meningitis)
2 h (LUTH) stool CTX-M-15, aac-(6¢)-lb-cr ST295
35 h (NOHI) wound swab CTX-M-15, aac-(6¢)-lb-cr ST448 (ST448 complex)
46 h (NOHI) catheter tip
LUTH, Lagos University Teaching Hospital; NOHI, National Orthopaedic Hospital Igbobi; PID, pelvic inﬂammatory disease.
Phylogenetic analysis of  the CTX-M-15 positive E. coliisolates
ST10_Cplx_ST48(n = 1)
ST23_Cplx_ST612(n = 1)
ST617(n = 3)
ST131(n = 5)
ST501(n = 1)
ST448(n = 2)
ST295(n = 1)
FIG. 1 Phylogenetic analysis of the CTX-M-15-positive Esherichia coli isolates (n = 14). Neighbour-joining tree constructed from the concate-
nated sequences of the seven MLST genes. Multiple sequence alignments and topology prediction were carried out with the DNASISMAX
(Hitachi Solutions, Ltd., Yokohama, Japan) version 2.0.5 (2003) program. The phylogenetic tree was resampled with 1000 bootstrap replications
to ensure the robustness of the data. The phylogenetic analyses were displayed with the TreeView program version 1.6.6. (Roderic D. M. Page,
Institute of Biomedical and Life Sciences, Glasgow, Scotland, UK).
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The ST617 belonging to the ST10 complex was docu-
mented to have occurred in CTX-M-14 in Spain [5]. STC 448
found in one of the blaCTX-M-15 strains has been documented
to have occurred in some non-ESBL pathogenic strains of
E. coli from Germany, Nigeria, India, Thailand and Scotland.
However, in Norway, an E. coli strain belonging to this
sequence type has also been reported but found to be associ-
ated with blaCMY-2 [20]. ST295 and ST501 have been docu-
mented in different pathogenic E. coli, such as EAEC, UPEC
and EPEC strains [12], but there are no previous reports of
CTX-M-15-producing E. coli occurring in these described clo-
nal strains. Neither SHV nor TEM ESBLs were found in this
study; CTX-M-15 was the predominant ESBL identiﬁed.
To the best of our knowledge, this study reports the ﬁrst
occurrence of CTX-M-15-producing E. coli strains from Nige-
ria belonging to ST131, ST617, ST23, ST295, ST448 and
ST501.
In summary, this study shows the great diversity of CTX-
M-15-producing isolates of E. coli that has emerged in the
south-western part of Nigeria. Not all isolates were of the
ST131 lineage, though the majority of the strains belong to
this lineage, while some of the strains were also found to
occur among other common clonal complexes of E. coli
worldwide, ST10 (ST627) and ST23. The presence of other
genetic lineages different from ST131 shows the continuing
potential for genetic diversiﬁcation and emergence of new
epidemic strains [21]. Association of these clones with plas-
mid-mediated quinolone resistance (qnr), aac-(6¢)-lb-cr and
ISEcp1 facilitating their spread is very worrisome.
Acknowledgement
This work was funded by the Alexander von Humboldt
Foundation, Germany. We extend special thanks to Soheila
Frotan and Andreas Jornitz for their assistance and Lysann
Hamel for performing the genotypic analysis by MLST.
Transparency Declaration
The study was supported by the Alexander von Humboldt
Foundation grant. The authors declare no conﬂict of
interests.
References
1. Ben Slama K, Sallem R, Jouini A et al. Diversity of genetic lineages
among CTX-M-15 and CTX-M-14 producing Escherichia coli strains in
a Tunisian hospital. Curr Microbiol 2011; 62: 1794–1801.
2. Lavollay M, Mamlouk K, Frank T et al. Clonal dissemination of a CTX-
M-15 b-lactamase-producing Escherichia coli strain in the Paris area,
Tunis, and Bangui. Antimicrob Agents Chemother 2006; 50: 2433–2438.
3. Livermore D, Canton R, Gniadkowski M et al. CTX-M: changing the
face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165–174.
4. Nicolas-Chanoine M, Blanco J, Leﬂon-Guibout V et al. Intercontinen-
tal emergence of Escherichia coli clone O25:H4-ST131 producing
CTX-M-15. J Antimicrob Chemother 2008; 61: 273–281.
5. Rogers B, Sidjabat H, Paterson D. Escherichia coli O25b-ST131: a
pandemic, multiresistant, community-associated strain. J Antimicrob
Chemother 2011; 66: 1–14.
6. Aibinu I, Ohaegbulam V, Adenipekun E, Ogunsola F, Odugbemi T, Mee
B. Extended-Spectrum b-Lactamase Enzymes in clinical isolates of Enterob-
acter species from Lagos, Nigeria. J Clin Microbiol 2003; 41: 2197–2200.
7. Aibinu I, Pfeifer Y, Ogunsola F, Odugbemi T, Koenig W, Ghebremed-
hin B. Emergence of b-lactamases OXA-10, VEB-1 and CMY in Provi-
dencia spp. from Nigeria. J Antimicrob Chemother 2011; 66: 1931–1932.
8. Olowe O, Grobbel M, Buchter B, Lu¨bke-Becker A, Fruth A, Wieler
L. Detection of blaCTX-M-15 Extended-spectrum b-lactamase genes
in Escherichia coli from hospitals in Nigeria. Int J Antimicrob Agents
2010; 35: 200–209.
9. Soge O, Queenan A, Ojo K, Adeniyi B, Roberts M. CTX-M-15
extended spectrum b-lactamase from Nigerian Klebsiella pneumoniae.
J Antimicrob Chemother 2006; 57: 24–30.
10. Wirth T, Falush D, Lan R et al. Sex and virulence in Escherichia coli:
an evolutionary perspective. Mol Microbiol 2006; 60: 1136–1151.
11. Clinical Laboratory Standards Institute. Performance standards for anti-
microbial susceptibility testing: 19th informational supplement M100S19.
Wayne, PA: Clinical Laboratory Standards Institute, 2009.
12. Boualle`gue-Godet O, Salem Y, Fabre L et al. Nosocomial outbreak
caused by Salmonella enterica serotype Livingstone producing CTX-M-
27 Extended-Spectrum b-Lactamase in a neonatal unit in Sousse,
Tunisia. J Clin Microbiol 2005; 43: 1037–1044.
13. Cano M, Rodrı´guez-Martı´nez J, Agu¨ero J et al. Detection of plasmid-
mediated quinolone resistance genes in clinical isolates of Enterobacter
spp. in Spain. J Clin Microbiol 2009; 47: 2033–2039.
14. Saladin M, Cao V, Lambert T et al. Diversity of CTX-M b-lactamases
and their promoter regions from Enterobacteriaceae isolated in three
Parisian hospitals. FEMS Microbiol Lett 2002; 209: 161–168.
15. Versalovic J, Koeuth T, Lupski J. Distribution of repetitive DNA
sequences in eubacteria and application to ﬁngerprinting of bacterial
genomes. Nucl Acids Res 1991; 19: 6823–6831.
16. Cagnacci S, Gualco L, Debbia E, Schito G, Marchese A. European
emergence of ciproﬂoxacin-resistant Escherichia coli clonal groups
O25:H4 ST131 and O15:K52:H1 causing community-acquired uncom-
plicated cystitis. J Clin Microbiol 2008; 46: 2605–2612.
17. Jones G, Warren R, Skidmore S, Davies V, Gibreel T, Upton M. Prev-
alence and distribution of plasmid-mediated quinolone resistance
genes in clinical isolates of Escherichia coli lacking extended-spectrum
beta-lactamases. J Antimicrob Chemother 2008; 62: 1245–1251.
18. Lau S, Reddy S, Cheesbrough J et al. Major uropathogenic Escherichia
coli strain isolated in the northwest of England identiﬁed by multilo-
cus sequence typing. J Clin Microbiol 2008; 46: 1076–1080.
19. Peirano G, van Greune C, Pitout J. Characteristics of infections caused by
extended-spectrum b-lactamase–producing Escherichia coli from commu-
nity hospitals in South Africa. Diagn Microbiol Inf Dis 2011; 69: 449–453.
20. Naseer U, Haldorsen B, Simonsen G, Sundsfjord A. Sporadic occur-
rence of CMY-2-producing multidrug-resistant Escherichia coli of ST-
complexes 38 and 448, and ST131 in Norway. Clin Microbiol Infect
2010; 16: 171–178.
21. Xu L, Shabir S, Bodah T et al. Regional survey of CTX-M-type
extended-spectrum b-lactamases among Enterobacteriaceae reveals
marked heterogeneity in the distribution of the ST131 clone. J Anti-
microb Chemother 2011; 66: 505–511.
CMI Research Note E51
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, E49–E51
